Xiamen Innovax Biotech Co. Ltd., a subsidiary of China's Yangshengtang Group in eastern China's Zhejiang Province, and Xiamen University have announced cooperation with British pharmaceutical giant GlaxoSmithKline (GSK), to do an evaluation for a recombinant protein-based vaccine candidate for Covid-19.
Gao Yongzhong, general manager of Xiamen Innovax, said that GSK will give an adjuvant framework that will be utilized in pre-clinical preliminaries for a vaccine candidate created by their organization and Xiamen University, UNB reports quoting Xinhua.
He added, "In combination with adjuvant system AS03, the recombinant protein-based vaccine candidate is expected to induce a high level of protective immunity to meet the urgent need for Covid-19 prevention,"
Thomas Breuer, GSK Vaccines chief medical officer, said that as one of their technological advantages, the adjuvant they produced can help enhance the body's immune response when it is added to the vaccine and an ideal combination is able to develop stronger and more durable immunity than a single vaccine.
"The use of adjuvant amid the Covid-19 pandemic is very important because it helps to produce more doses of vaccine and allows more people to be vaccinated," said Breuer.
According to GSK, the adjuvant can expand the immunogenicity, reaction speed and resistance of antigens and in the interim lessen their utilization. At the point when a similar portion of vaccine antigen meets a perfect adjuvant, it can deliver more vaccines with a similar impact simultaneously, which is useful to large scale manufacturing of vaccines for the pandemic.
At the moment, the cooperation between the three parties incorporates pre-clinical preliminaries in the first period and if it is detected to show good prospects, they will at that point start clinical preliminaries.
